Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04230213 · ClinicalTrials.gov registry record · Phase 3
A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 455
- Enrollment target
NCT04230213 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 455 participants.
The verdict
NCT04230213, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 455 participants
- Enrollment target
Study Summary
The study will assess the impact of pharmacokinetics (PK), safety and immunogenicity after switches between PF-06410293 and adalimumab and with continuous dosing with adalimumab in combination with methotrexate in subjects with moderately to severely active rheumatoid arthritis.
Interventions
- DRUG adalimumab
- DRUG PF-06410293
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2021-06-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04230213
The ClinicalTrials.gov registry entry for NCT04230213 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 455 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which adalimumab is the first listed.
NCT04230213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04230213 about?
NCT04230213 is a clinical study titled "A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis". The study will assess the impact of pharmacokinetics (PK), safety and immunogenicity after switches between PF-06410293 and adalimumab and with continuous dosing with adalimumab in combination with methotrexate in subjects with moderately to severely active rheumatoid arthritis.
What is the current status of trial NCT04230213?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 455 participants. The study started on 2020-01-13. Estimated completion is 2021-06-22.
What interventions are being tested in trial NCT04230213?
The interventions under investigation include: adalimumab (DRUG), PF-06410293 (DRUG).
Who is sponsoring clinical trial NCT04230213?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.